AHPAW Depositi SEC - OmniAb Inc - Warrants (01/11/2027)- Relazione annuale, dichiarazione di delega, prospetto informativo

Statistiche di base

LEI	549300RLC2O821TU6941
CIK	1661181

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to OmniAb Inc - Warrants (01/11/2027)

SEC Filings (Chronological Order)

Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.

May 7, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2026 ORGANOGENESIS HOLDING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2026 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commission
May 7, 2026	EX-99.1	Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results CANTON, Mass., (May 7, 2026) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medici
May 7, 2026	EX-10.2	For purposes of this Agreement, "Cause" shall mean: Exhibit 10.2 KEY EMPLOYEE RETENTION AGREEMENT This Key Employee Retention Agreement (this “Agreement”) is entered into as of [date], by and between Organogenesis Holdings Inc., a Delaware corporation with its principal offices located at 85 Dan Road, Canton, Massachusetts 02021 (together with its successors and assigns, the "Company"), and [name of executive] (the "Executive"). This Agreement supe
May 7, 2026	EX-10.1	For purposes of this Agreement, "Cause" shall mean: Exhibit 10.1 KEY EMPLOYEE RETENTION AGREEMENT This Key Employee Retention Agreement (this “Agreement”) is entered into as of May 6, 2026, by and between Organogenesis Holdings Inc., a Delaware corporation with its principal offices located at 85 Dan Road, Canton, Massachusetts 02021 (together with its successors and assigns, the "Company"), and Gary S. Gillheeney, Sr. (the "Executive"). This Agree
May 7, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
April 30, 2026	ARS	ARS 2025 ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ն TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
April 30, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De
February 26, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 26, 2026 ORGANOGENESIS H UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 26, 2026 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
February 26, 2026	EX-4.1	DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the capital stock of Organogenesis Holdings Inc. (the “Company,” “we,” “us,” and “our”) and the material provisions of our restated certificate of incorporation, as amended (“restated certificate of incorporation”), our certificate of designati
February 26, 2026	EX-21.1	SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. Exhibit 21.1 SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. NAME OF ORGANIZATION JURISDICTION Organogenesis Inc. Delaware Prime Merger Sub, LLC Delaware Organogenesis Switzerland GmbH Switzerland
February 26, 2026	EX-99.1	Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue CANTON, Mass., (February 26, 2026) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and s
February 26, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
February 23, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) ff the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 18, 2026 ORGANOGENESIS H UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) ff the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 18, 2026 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
December 29, 2025	EX-10.2	FIRST AMENDMENT TO LEASE EX-10.2 Exhibit 10.2 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) dated as of December 22, 2025, is entered into between Dan Road Associates, LLC, a Massachusetts limited liability company, with an address at c/o Draxxhall Management Corp., 300 Lighting Way, Suite 613, Secaucus, NJ 07094 (“Landlord”), and Organogenesis Inc., a Delaware corporation, with an address at 8
December 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 22, 2025 ORGANOGENESIS H UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 22, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
December 29, 2025	EX-10.1	FIRST AMENDMENT TO LEASE EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) dated as of December 22, 2025, is entered into between 65 Dan Road SPE, LLC, a Delaware limited liability company, with an address at c/o Draxxhall Management Corp., 300 Lighting Way, Suite 613, Secaucus, NJ 07094 (“Landlord”), and Organogenesis Inc., a Delaware corporation, with an address at 85 Dan Roa
November 6, 2025	EX-10.2	As to each and every Claim released hereunder, each Loan Party expressly waives all rights afforded by Section 1542 of the Civil Code of the State of California (“Section 1542”) and any similar statute or regulation in any other applicable jurisdicti Exhibit 10.2 Execution Version FIFTH AMENDMENT TO CREDIT AGREEMENT This Fifth Amendment to Credit Agreement (this “Amendment”) dated and effective as of October 31, 2025 (the “Fifth Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (the “Borrower”), the several banks and other financial institutions or entities party hereto constituting the Required Lender
November 6, 2025	EX-99.1	Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance CANTON, Mass., (November 6, 2025) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical
November 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2025 ORGANOGENESIS HO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commi
November 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
September 25, 2025	EX-99.1	Organogenesis Provides Update on Second Phase 3 ReNu® Study Company maintains confidence in ReNu as innovative pain management therapy EX-99.1 Exhibit 99.1 Organogenesis Provides Update on Second Phase 3 ReNu® Study Company maintains confidence in ReNu as innovative pain management therapy • Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpoint • Statistically significant maintenance of function (p<0.0001) • Company will request pre
September 25, 2025	EX-99.2	Table 14.2.1.1 Change from Baseline WOMAC Pain Scale at 6 Months - Control-based Mean Imputation FAS Population Statistics ASA (N = 296) Placebo (N = 298) WOMAC Pain Scale Change from Baseline to Week 26 n 244 252 Mean (SD) -7.0 (4.55) -6.5 (4.89) Me EX-99.2 Exhibit 99.2 Organogenesis 22OA (Second Phase 3 ReNu Study) Table 14.2.1.1 Change from Baseline WOMAC Pain Scale at 6 Months - Control-based Mean Imputation FAS Population Statistics ASA (N = 296) Placebo (N = 298) WOMAC Pain Scale Change from Baseline to Week 26 n 244 252 Mean (SD) -7.0 (4.55) -6.5 (4.89) Median -7.0 -6.0 Q1, Q3 -11.0, -4.0 -10.0, -3.0 Min, Max -20, 4 -20, 6 Number of sub
September 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 25, 2025 ORGANOGENESIS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 25, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Com
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
August 7, 2025	S-8	Power of Attorney (included on the signature page hereto) S-8 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 7, 2025 REGISTRATION NO.
August 7, 2025	EX-10.1	Fourth Amendment to Credit Agreement dated as of August 5, 2025 by and among the Company, the lenders named therein and the administrative agent Exhibit 10.1 Execution Version FOURTH AMENDMENT TO CREDIT AGREEMENT This Fourth Amendment to Credit Agreement (this “Amendment”) dated and effective as of August 5, 2025 (the “Fourth Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (the “Borrower”), the several banks and other financial institutions or entities party hereto constituting the Required Lende
August 7, 2025	EX-99.1	Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results CANTON, Mass., (August 7, 2025) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financ
August 7, 2025	EX-FILING FEES	Filing Fee Table Calculation of Filing Fee Tables S-8 Organogenesis Holdings Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Class A Common Stock, $0.0001 par value per share Other 15,900,000 $ 4.485 $ 71,311,500.00 0.0001531 $ 10
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 ORGANOGENESIS HOLD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss
June 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2025 ORGANOGENESIS HOLDI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissi
May 12, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
May 8, 2025	EX-99.1	Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results CANTON, Mass., (May 8, 2025) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial
May 8, 2025	EX-10.1	First Amendment to Lease dated March 21, 2025 among Organogenesis Holdings Inc., Organogenesis Inc., and DIV Technology Way, LLC Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of March 21, 2025, by and between DIV TECHNOLOGY WAY, LLC, a Delaware limited liability company (“Landlord”), and ORGANOGENESIS HOLDINGS INC., a Delaware corporation and ORGANOGENESIS INC., Delaware corporation (collectively, jointly and severally, “Tenant”). R E C I T A L S: A. Landlord and T
May 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2025 ORGANOGENESIS HOLDING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commission
April 29, 2025	PRE 14A	PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 29, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PUR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
March 27, 2025	EX-99.1	FORWARD LOOKING STATEMENTS & OTHER IMPORTANT CAUTIONS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecas Exhibit 99.1 INVESTOR PRESENTATION March 2025 FORWARD LOOKING STATEMENTS & OTHER IMPORTANT CAUTIONS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,
March 27, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss
February 27, 2025	EX-10.35	Lease dated as of November 18, 2024 by and between DIV Technology Way, LLC and Organogenesis Holdings Inc. Exhibit 10.35 Execution Copy LEASE between DIV TECHNOLOGY WAY, LLC, as Landlord and ORGANOGENESIS HOLDINGS INC. and ORGANOGENESIS INC., as Tenant 100 Technology Way Smithfield, Rhode Island November 18, 2024 TABLE OF CONTENTS ARTICLE 1 GRANT 1 ARTICLE 2 TERM 3 ARTICLE 3 COMPLETION AND OCCUPANCY OF THE PREMISES 4 ARTICLE 4 RENT AND SECURITY 4 ARTICLE 5 ADDITIONAL RENT FOR REAL ESTATE TAXES AND OPER
February 27, 2025	EX-19.1	Organogenesis Holdings Inc. Amended and Restated Insider Trading Compliance Policy Exhibit 19.1 ORGANOGENESIS HOLDINGS INC. AMENDED AND RESTATED INSIDER TRADING COMPLIANCE POLICY Updated April 19, 2023 CONTENTS Page I. SUMMARY 1 II. STATEMENT OF POLICIES PROHIBITING INSIDER TRADING 1 III. EXPLANATION OF INSIDER TRADING 2 IV. STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING 6 V. ADDITIONAL PROHIBITED TRANSACTIONS 9 VI. RULE 10b5-1 TRADING PLANS, SECTION 16 AND RULE 144 11 VII.
February 27, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2025 ORGANOGENESIS H UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2025 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
February 27, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
February 27, 2025	EX-10.36	Form of Performance Share Award Agreement under the 2018 Equity Incentive Plan Exhibit 10.36 ORGANOGENESIS HOLDINGS INC. Performance Share Award Agreement Organogenesis Holdings Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (the “Plan”), hereby grants this Performance Share Award (this “Award”) to the Recipient named below. The terms and conditions of this Award are set forth in this Performance Share Award Agreement (this “Agreement”), consisting of this
February 27, 2025	EX-10.37	Employee Letter Agreement dated as of July 30, 2021 by and between Organogenesis Inc. and Robert Cavorsi July 30, 2021 Robert Cavorsi Dear Rob, Congratulations! I am pleased to inform you that you have been recommended for a promotion and it has been approved.
February 27, 2025	EX-99.1	Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results CANTON, Mass., (February 27, 2025) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports med
February 27, 2025	EX-21.1	Subsidiaries of Organogenesis Holdings Inc. Exhibit 21.1 SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. NAME OF ORGANIZATION JURISDICTION Organogenesis Inc. Delaware Prime Merger Sub, LLC Delaware Organogenesis Switzerland GmbH Switzerland
February 27, 2025	EX-4.1	Description of Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the capital stock of Organogenesis Holdings Inc. (the “Company,” “we,” “us,” and “our”) and the material provisions of our restated certificate of incorporation, as amended (“restated certificate of incorporation”), our certificate of designati
January 3, 2025	EX-99.23	ORGO / Organogenesis Holdings Inc. / Ades Alan A. - EX-99.23 begin 644 orgo-ex9923.pdf M)5!$1BTQ+C<-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V%L@," P(#8Q,B W.3)=("]# M;VYT96YT4ENYPPXZ/7$=%^+N& N\^'0238 M(CX]^<\[EIZ>7-^?GES<<@8W[B>G)QP>CSE.GR;'*B!&>O0=C'+S>,O98.MRH=38T?>8Y[$#7"C5"2"<F!]R M1]3)N?O]\VWJ!=V^E7U-+GWSZQJT]?!R&6FM?ADH?P&,'4OL$B3#T'&E MB: >\I''R*=.CJL<%3'?#QS526HG1%"\HDF27I M$SHI5DP3Y"\[email protected]%Z,B'LK!.!-4H@WBINHB3)802 S.=9FI,E/("6)^#FL@48 M#?F[@J
January 3, 2025	EX-99.25	ORGO / Organogenesis Holdings Inc. / Ades Alan A. - EX-99.25 begin 644 orgo-ex9925.pdf M)5!$1BTQ+C<-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V%L@," P(#8Q,B W.3)=("]# M;VYT96YT=^S??+ 5GUZNT@%>O MSMY?O'L-\NRGM%C "].[@>3R8P?7T!?QT?22'I7Z("D!#BWR@)X%-^?/2 M'Z X/IK>'!^=O5&@E) &;FZ/CQ3>)T&!2:R(( HB$VHX?QJ1Y!DHC CO\/-U?'1YH8VTL M5$<=UJ(2#MMBX/+]!<"V>Y1O]U3Z"N"Y^@3O$2?8$"?P$9":XAD(+3I:73U MO$ $D&P+"94([3XAO[S[&;/@]>7O\%QI V8E&/!DG\1S/V9I:46L]@EY.U9V M]/OE)67U>IS^
January 3, 2025	EX-99.26	ORGO / Organogenesis Holdings Inc. / Ades Alan A. - EX-99.26 begin 644 orgo-ex9926.pdf M)5!$1BTQ+C<-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V4O4&%R96YT(#(@,"!2+U)E%L@," P(#8Q M,B W.3)=("]#;VYT96YTS]NS MFJW>OSN>?N](IE<./FOT[!HVC&6&YP67F9$R+V5V\PB-/EZ;;+Z#%V9S M.BO=V3%4KMUXM??LJ MT^:K.;98+8:>UZ^(-RX83L&/$#@<5DP9+PGCP4SXB7<\3<\(+E$M@I6'Z^,L$PW4'W\;BL&GBZ$<'QV/=1V]+SCY\N+['UKW"#+OUVDTC? M)2MR5RF7 SH>B$8H^/EXI.&87XR9P&MZ/,+? M0HQ'K*@Z5["UX&,\Y'
January 3, 2025	EX-99.24	ORGO / Organogenesis Holdings Inc. / Ades Alan A. - EX-99.24 begin 644 orgo-ex9924.pdf M)5!$1BTQ+C<-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+T=R;W5P+U,O M5')A;G-P87)E;F-Y+T-3+T1E=FEC95)'0CX^+U1A8G,O4R]3=')U8W1087)E M;G1S(# ^/@T96YD;V)J#0HT(# @;V)J#0H\/"]&:6QT97(O1FQA=&5$96-O M9&4O3&5N9W1H(#(X,38^/@T9%>.) M8\=)5M5(0&&WW9;M!59H5>V', 2(=CI#&0.7^^NOSW'B.!.;4FJ*-)G$SOB\ M^+P\/C;3W5M97Y9S&;UY,]V5LIQ?5Q?1Y^G>2LK5EW^FIX\WU?13>54O2UFO MEM.3NW,)38>KE:QN9[-H[^U
December 23, 2024	424B3	Up to 130,000 Shares of Series A Convertible Preferred Stock Offered by the Selling Stockholders Up to 34,285,653 Shares of Class A Common Stock Issuable Upon Conversion of Series A Convertible Preferred Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-283934 PROSPECTUS Up to 130,000 Shares of Series A Convertible Preferred Stock Offered by the Selling Stockholders Up to 34,285,653 Shares of Class A Common Stock Issuable Upon Conversion of Series A Convertible Preferred Stock On November 12, 2024, we consummated a private placement (the “Private Placement”) pursuan
December 20, 2024	LETTER	LETTER December 20, 2024 Gary Gillheeney Chief Executive Officer Organogenesis Holdings Inc.
December 20, 2024	CORRESP	Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 Acceleration Request Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 December 20, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Organogenesis Holdings Inc. Registration Statement on Form S-3 File No. 333-283934 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated u
December 19, 2024	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Organogenesis Holdings Inc.
December 19, 2024	S-3	As filed with the Securities and Exchange Commission on December 19, 2024 Table of Contents As filed with the Securities and Exchange Commission on December 19, 2024 Registration Statement No.
December 2, 2024	EX-10.1	Stock Repurchase Agreement, dated November 27, 2024, by and between Organogenesis Holdings Inc. and GN 2016 Family Trust u/a/d August 12, 2016 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on December 2, 2024) Exhibit 10.1 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 27, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and GN 2016 Family Trust u/a/d August 12, 2016 (the “Selling Stockholder”). Recitals WHEREAS, the Selling Stockholder has expressed interest to the Company (the “Indication of Interest
December 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 27, 2024 ORGANOGENESIS H UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 27, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
November 22, 2024	EX-99.1	Organogenesis Expands Manufacturing Capacity to Support Future Growth Organogenesis Expands Manufacturing Capacity to Support Future Growth CANTON, Mass.
November 22, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 18, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
November 19, 2024	SC 13D	ORGO / Organogenesis Holdings Inc. / Avista Healthcare Partners III, L.P. - SC 13D Activist Investment SC 13D 1 d896717dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Organogenesis Holdings Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Avista Healthcare Partners 65 East 55th Street, 18th Floor New Yor
November 19, 2024	EX-99.4	Power of Attorney of David Burgstahler and Thompson Dean (filed herewith) EX-99.4 3 d896717dex994.htm EX-99.4 Exhibit 99.4 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Benjamin Silbert with full power of substitution, the undersigned’s true and lawful attorney-in-fact to: 1. execute for and on behalf of the undersigned with respect to Organogenesis Holdings Inc. (the “Company”), Schedules 13D and 13G and Forms 3, 4,
November 19, 2024	EX-99.1	Joint Filing Agreement, dated November 19, 2024, by and among Avista Healthcare Partners III, LP, AHP III Orchestra Holdings, L.P., Avista Capital Partners VI GP, L.P., Avista Capital Managing Member VI, LLC, David Burgstahler and Thompson Dean (filed herewith) EX-99.1 2 d896717dex991.htm EX-99.1 Exhibit 99.1 Joint Filing Agreement Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 13d-1(k)(1) thereunder, the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13(d) of the Exchange Act or any rule or regulation thereunder (
November 14, 2024	EX-99.19	STOCK REPURCHASE AGREEMENT EX-99.19 3 d899462dex9919.htm EX-99.19 Exhibit 99.19 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and Albert Erani (the “Selling Stockholder”). Recitals WHEREAS, on November 12, 2024, the Company entered into a Subscription Agreement by and a
November 14, 2024	EX-99.20	STOCK REPURCHASE AGREEMENT EX-99.20 4 d899462dex9920.htm EX-99.20 Exhibit 99.20 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and Glenn H. Nussdorf (the “Selling Stockholder”). Recitals WHEREAS, on November 12, 2024, the Company entered into a Subscription Agreement by
November 14, 2024	SC 13G/A	ORGO / Organogenesis Holdings Inc. / Soleus Capital Master Fund, L.P. - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea0221047-13ga3soleusorgan.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ORGANOGENESIS HOLDINGS INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 68621F102 (CUSIP Number) September 30, 2024 (Date of Event Whi
November 14, 2024	EX-99.21	STOCK REPURCHASE AGREEMENT EX-99.21 5 d899462dex9921.htm EX-99.21 Exhibit 99.21 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and the Alan Ades 2014 GRAT (the “Selling Stockholder”). Recitals WHEREAS, on November 12, 2024, the Company entered into a Subscription Agreeme
November 14, 2024	SC 13D/A	ORGO / Organogenesis Holdings Inc. / Ades Alan A. - SC 13D/A Activist Investment SC 13D/A 1 d899462dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Chief Administrative and Legal Officer Organogenesis Holdi
November 14, 2024	EX-99.18	STOCK REPURCHASE AGREEMENT EX-99.18 2 d899462dex9918.htm EX-99.18 Exhibit 99.18 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and Alan A. Ades (the “Selling Stockholder”). Recitals WHEREAS, on November 12, 2024, the Company entered into a Subscription Agreement by and a
November 14, 2024	EX-99.22	STOCK REPURCHASE AGREEMENT EX-99.22 6 d899462dex9922.htm EX-99.22 Exhibit 99.22 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and RED Holdings, LLC (the “Selling Stockholder”). Recitals WHEREAS, on November 12, 2024, the Company entered into a Subscription Agreement by
November 13, 2024	EX-99.1	Organogenesis Holdings Inc. Announces $130 million Private Placement Offering of Series A Convertible Preferred Stock Net proceeds to fund the Company’s strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Announces $130 million Private Placement Offering of Series A Convertible Preferred Stock Net proceeds to fund the Company’s strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases CANTON, Mass. (November 12, 2024) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regene
November 13, 2024	EX-10.2	Third Amendment to Credit Agreement dated as of November 12, 2024 by and among the Company, the lenders named therein and the administrative agent (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on November 13, 2024) Exhibit 10.2 Execution Version THIRD AMENDMENT TO CREDIT AGREEMENT This Third Amendment to Credit Agreement (this “Amendment”) dated and effective as of November 12, 2024 (the “Third Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (the “Borrower”), the several banks and other financial institutions or entities party hereto constituting the Required Lende
November 13, 2024	EX-10.3	Form of Stock Repurchase Agreement, dated November 12, 2024 (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on November 13, 2024) Exhibit 10.3 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of November 12, 2024, by and between Organogenesis Holdings Inc., a Delaware corporation (the “Company”), and [] (the “Selling Stockholder”). Recitals WHEREAS, on November 12, 2024, the Company entered into a Subscription Agreement by and among the Company, Avista Healthcare Partners III,
November 13, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
November 13, 2024	EX-10.1	Subscription Agreement, dated November 12, 2024, by and among Organogenesis Holdings Inc., Avista Healthcare Partners III, L.P. and AHP III Orchestra Holdings, L.P. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on November 13, 2024) Exhibit 10.1 Execution Version SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (the “Agreement”) is entered into this 12th day of November, 2024, by and among, Organogenesis Holdings Inc., a Delaware corporation (the “Company”), Avista Healthcare Partners III, L.P., a Delaware limited partnership (“Avista Onshore”) and AHP III Orchestra Holdings, L.P., a Delaware limited partnership (“Avista Ho
November 12, 2024	EX-99.1	Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results CANTON, Mass., (November 12, 2024) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported fina
November 12, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
November 12, 2024	EX-3.3	Certificate of Designations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on November 12, 2024) Organogenesis Holdings Inc. Certificate of Designations Series A Convertible Preferred Stock November 12, 2024 IF " DOCVARIABLE "SWDocIDLocation" 1" = "1" " DOCPROPERTY "SWDocID" 12596845.1" "" 12596845.1 Table of Contents Page Section 1. Definitions 1 Section 2. Rules of Construction 14 Section 3. The Convertible Preferred Stock 14 (a) Designation; Par Value 14 (b) Number of Authorized Shares 14
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
August 13, 2024	LETTER	LETTER August 13, 2024 Gary S. Gillheeney Chief Executive Officer, President and Chair of the Board of Directors Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 Re: Organogenesis Holdings Inc. Registration Statement on Form S-3 Filed August 8, 2024 File No. 333-281392 Dear Gary S. Gillheeney: This is to advise you that we have not reviewed and will not review your registration stateme
August 13, 2024	CORRESP	Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 August 13, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Organogenesis Holdings Inc. Registration Statement on Form S-3 File No. 333-281392 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 19
August 8, 2024	S-3	As filed with the Securities and Exchange Commission on August 8, 2024 Table of Contents As filed with the Securities and Exchange Commission on August 8, 2024 Registration Statement No.
August 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss
August 8, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Organogenesis Holdings Inc.
August 8, 2024	EX-99.1	Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results CANTON, Mass., (August 8, 2024) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financ
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
August 8, 2024	EX-4.1	Form of Indenture Exhibit 4.1 ORGANOGENESIS HOLDINGS INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 5 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 6 Section 2.01 Issuable in Series 6 Section 2.02 Esta
June 21, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 20, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissi
June 21, 2024	EX-10.1	2018 Equity Incentive Plan (as amended) Exhibit 10.1 ORGANOGENESIS HOLDINGS INC. 2018 EQUITY INCENTIVE PLAN Section 1. Purposes of the Plan The purposes of the Organogenesis Holdings Inc. 2018 Equity Incentive Plan (the “Plan”) are to (i) provide long-term incentives and rewards to those employees, officers, directors and other key persons (including consultants) of Organogenesis Holdings Inc. (the “Company”) and its Subsidiaries (as de
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commission
May 9, 2024	EX-99.1	Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results CANTON, Mass., (May 9, 2024) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial
April 29, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De
April 29, 2024	ARS	ARS 2023 ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
April 3, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 3, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissi
April 3, 2024	EX-99.1	Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case Exhibit 99.1 Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case April 3, 2024 at 7:30 AM EDT CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine mar
February 29, 2024	EX-21.1	Subsidiaries of Organogenesis Holdings Inc. Exhibit 21.1 SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. NAME OF ORGANIZATION JURISDICTION Organogenesis Inc. Delaware Prime Merger Sub, LLC Delaware Organogenesis Switzerland GmbH Switzerland
February 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
February 29, 2024	EX-99.1	Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance CANTON, Mass., (February 29, 2024) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care
February 29, 2024	EX-97.1	Organogenesis Holdings Inc. Compensation Recovery Policy as adopted on November 1, 2023 ORGANOGENESIS HOLDINGS INC. Compensation Recovery Policy November 1, 2023 This Compensation Recovery Policy (the “Policy”) has been adopted by the Board of Directors (the “Board”) of Organogenesis Holdings Inc. (the “Company”). Certain capitalized terms used in this Policy are defined at the end of this Policy. 1. Introduction. This Policy is intended to support the Company’s pay-for-performance p
February 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):February 29, 2024 ORGANOGENESIS HO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):February 29, 2024 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commi
February 9, 2024	SC 13G	ORGO / Organogenesis Holdings Inc. / MORGAN STANLEY - MS INITIAL Passive Investment SC 13G 1 OrganogenesisHoldingsORGO.txt MS INITIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Organogenesis Holdings Inc. - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 68621F102 - (CUSIP Number) December 31, 2023 - (Date Of Event which Requires Filing of this Statement) Ch
February 2, 2024	SC 13G/A	ORGO / Organogenesis Holdings Inc. / Soleus Capital Master Fund, L.P. - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea192415-13ga2soleusorgan.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Organogenesis Holdings Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 68621F102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of t
November 9, 2023	EX-99.1	Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results CANTON, Mass., (November 9, 2023) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported finan
November 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2023 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commi
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
August 9, 2023	EX-99.1	Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance CANTON, Mass., (August 9, 2023) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Me
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
August 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2023 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss
June 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 13, 2023 ORGANOGENESIS HOLDI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 13, 2023 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissi
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
May 10, 2023	EX-10	Second Amendment to Credit Agreement dated and effective as of April 17, 2023 by and among Organogenesis Holdings Inc., as borrower, the several banks and other financial institutions or entities party hereto and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), as the Administrative Agent (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on May 10, 2023) Exhibit 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT This Second Amendment to Credit Agreement (this “Amendment”) dated and effective as of April 17, 2023 (the “Second Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (the “Borrower”), the several banks and other financial institutions or entities party hereto constituting the Required Lenders (as defined in
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 ORGANOGENESIS HOLDIN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissio
May 10, 2023	EX-99	Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results CANTON, Mass., (May 10, 2023) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial
May 1, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
May 1, 2023	ARS	ARS 2022 ANNUAL REPORTUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
April 6, 2023	SC 13G/A	ORGO / Organogenesis Holdings Inc - Class A / BlackRock Inc. Passive Investment us68621f1021040523.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Organogenesis Holdings Inc. - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 68621F102 - (CUSIP Number) March 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
March 1, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
March 1, 2023	EX-99	Organogenesis Holdings Inc. Reports Fourth Quarter 2022and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Fourth Quarter 2022and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance CANTON, Mass., (March 1, 2023) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and
March 1, 2023	EX-21	Subsidiaries of Organogenesis Holdings Inc. Exhibit 21.1 SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. NAME OF ORGANIZATION JURISDICTION Organogenesis Inc. Delaware Prime Merger Sub, LLC Delaware Organogenesis Switzerland GmbH Switzerland
March 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):March 1, 2023 ORGANOGENESIS HOLDIN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):March 1, 2023 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissio
March 1, 2023	EX-10	First Amendment to Credit Agreement dated as of December 8, 2022 by and among Organogenesis Holdings Inc., as borrower, the several banks and other financial institutions or entities party hereto and Silicon Valley Bank, as the Administrative Agent, and as the Issuing Lender and the Swingline Lender (incorporated by reference to Exhibit 10.33 to the Company’s Annual Report on Form 10-K (File No. 001-37906) filed with the SEC on March 1, 2023) EXHIBIT 10.33 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT This First Amendment to Credit Agreement (this “Amendment”) dated and effective as of December 8, 2022 (the “First Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (the “Borrower”), the several banks and other financial institutions or entities party hereto (the “Lenders”) and SILICON VAL
February 14, 2023	SC 13G/A	ORGO / Organogenesis Holdings Inc / Soleus Capital Master Fund, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d458587dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Organogenesis Holdings Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 68621F102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria
February 10, 2023	SC 13G/A	ORGO / Organogenesis Holdings Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 3, 2023	SC 13G/A	ORGO / Organogenesis Holdings Inc / BlackRock Inc. Passive Investment us68621f1021020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Organogenesis Holdings Inc. - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 68621F102 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
December 9, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Organogenesis Holdings Inc.
December 9, 2022	S-8	AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 9, 2022 S-8 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 9, 2022 REGISTRATION NO.
November 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
November 9, 2022	EX-99.1	Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results CANTON, Mass., (November 9, 2022) - Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results
November 9, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):November 9, 2022 ORGANOGENESIS HOL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported):November 9, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commis
October 13, 2022	SC 13G	ORGO / Organogenesis Holdings Inc / Soleus Capital Master Fund, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Organogenesis Holdings Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 68621F102 (CUSIP Number) October 11, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
October 13, 2022	EX-99.A	JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Mr. Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments t
August 9, 2022	EX-99.1	Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results CANTON, Mass., (August 9, 2022) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financ
August 9, 2022	EX-10.1	2018 Equity Incentive Plan (as amended) (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on June 21, 2024) Exhibit 10.1 ORGANOGENESIS HOLDINGS INC. 2018 EQUITY INCENTIVE PLAN Section 1. Purposes of the Plan The purposes of the Organogenesis Holdings Inc. 2018 Equity Incentive Plan (the ?Plan?) are to (i) provide long-term incentives and rewards to those employees, officers, directors and other key persons (including consultants) of Organogenesis Holdings Inc. (the ?Company?) and its Subsidiaries (as de
August 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
June 27, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissi
June 27, 2022	EX-3.1	Certificate of Amendment of Certificate of Incorporation of Organogenesis Holdings Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on June 27, 2022) Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ORGANOGENESIS HOLDINGS INC. Organogenesis Holdings Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: That the Board of Directors of the Corporation duly adopted resolutions setting forth the proposed amendment
May 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissio
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter ly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter ly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
May 10, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
May 10, 2022	EX-99.1	Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results CANTON, Mass., (May 10, 2022) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial
May 5, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commission
May 5, 2022	EX-99.1	Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Appoints Michele Korfin and Gilberto Quintero, Ph.D. to Board of Directors CANTON, Mass., May 5, 2022 ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today annou
April 29, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ☐ TRANSITION REPORT PUR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
April 29, 2022	PRE 14A	PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents PRELIMINARY PROXY STATEMENT ? SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 15, 2022	8-K	Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 15, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss
March 1, 2022	EX-99.1	Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance CANTON, Mass., (March 1, 2022) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surg
March 1, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 1, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissi
March 1, 2022	EX-21.1	Subsidiaries of Organogenesis Holdings Inc. Exhibit 21.1 SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. NAME OF ORGANIZATION JURISDICTION Organogenesis Inc. Delaware Prime Merger Sub, LLC Delaware Organogenesis Switzerland GmbH Switzerland
March 1, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ☐ TRANSITION REPORT PURSU Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
February 18, 2022	EX-99.1	Organogenesis Appoints Michael J. Driscoll, Ed.D. to Board of Directors Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Appoints Michael J. Driscoll, Ed.D. to Board of Directors CANTON, Mass., February 17, 2022 ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the ap
February 18, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 15, 2022 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
February 11, 2022	SC 13G/A	ORGO / Organogenesis Holdings Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 4, 2022	SC 13G	ORGO / Organogenesis Holdings Inc / BlackRock Inc. Passive Investment us68621f1021020422.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Organogenesis Holdings Inc - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 68621F102 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r
December 30, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 29, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
December 30, 2021	SC 13D/A	ORGO / Organogenesis Holdings Inc / Ades Alan A. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Vice President and General Counsel Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02
December 17, 2021	SC 13D/A	ORGO / Organogenesis Holdings Inc / Ades Alan A. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Vice President and General Counsel Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02
November 30, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
November 22, 2021	EX-99.1	Organogenesis Appoints Prathyusha Duraibabu to Board of Directors Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Appoints Prathyusha Duraibabu to Board of Directors CANTON, Mass., November 22, 2021 ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointm
November 22, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
November 9, 2021	EX-99.1	Three Months Ended September 30, Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter and First Nine Months 2021 Financial Results CANTON, Mass. (November 9, 2021) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets,
November 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commi
November 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION R Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS
August 16, 2021	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commis
August 16, 2021	EX-10.1	Purchase and Sale Agreement dated as of August 11, 2021 by and between Organogenesis Inc. and 275 Dan Road SPE, LLC Exhibit 10.1 Execution Version PURCHASE AND SALE AGREEMENT (275 DAN ROAD, CANTON, MASSACHUSETTS) THIS PURCHASE AND SALE AGREEMENT (the ?Agreement?) is made this 11th day of August, 2021 (the ?Effective Date?), by and between ORGANOGENESIS INC., a Delaware corporation (?Buyer?), and 275 DAN ROAD SPE, LLC, a Delaware limited liability company (?Seller?). WITNESSETH: WHEREAS, Seller is the owner of t
August 9, 2021	10-Q	Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC.
August 9, 2021	EX-99.1	Organogenesis Holdings Inc. Reports Second Quarter and First Half 2021 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter and First Half 2021 Financial Results CANTON, Mass. (August 9, 2021) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today r
August 9, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss
August 9, 2021	EX-10.1	Credit Agreement dated and effective as of August 6, 2021 among Organogenesis Holdings Inc., as borrower, Organogenesis Inc. and Prime Merger Sub, LLC, as guarantors, and Silicon Valley Bank, as Administrative Agent, Lead Arranger, Bookrunner, Issuing Lender and Swingline Lender, and Silicon Valley Bank and the several other lenders from time to time party thereto, collectively as Lenders. Exhibit 10.1 Execution Version SENIOR SECURED CREDIT FACILITIES CREDIT AGREEMENT dated as of August 6, 2021, among ORGANOGENESIS HOLDINGS INC., as the Borrower, THE SEVERAL LENDERS FROM TIME TO TIME PARTY HERETO, SILICON VALLEY BANK, as Administrative Agent, Joint Lead Arranger, Bookrunner, Issuing Lender and Swingline Lender and BANK OF AMERICA, N.A., CITIZENS BANK N.A. and PNC CAPITAL MARKETS LL
August 9, 2021	EX-99.2	Organogenesis Holdings Inc. Announces New $200 Million Credit Agreement with Silicon Valley Bank Exhibit 99.2 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Announces New $200 Million Credit Agreement with Silicon Valley Bank CANTON, Mass. (August 9, 2021) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets,
July 9, 2021	SC 13G	ORGO / Organogenesis Holdings Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
May 29, 2021	SC 13D/A	ORGO / Organogenesis Holdings Inc / Ades Alan A. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Vice President and General Counsel Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02021 Tel:
May 27, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 24, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commissio
May 26, 2021	SC 13D/A	ORGO / Organogenesis Holdings Inc / Avista Acquisition Corp. - SC 13DA Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.
May 18, 2021	SC 13D/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No. 5) (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Organogenesis Holdings Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Cl SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.
May 11, 2021	EX-10.4	Form of Change in Control Retention Agreement (Independent Directors) (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on May 10, 2021) Exhibit 10.4 CHANGE IN CONTROL RETENTION AGREEMENT This Change in Control Retention Agreement (this ?Agreement?) is entered into as of [DATE], by and between Organogenesis Holdings Inc., a Delaware corporation with its principal offices located at 85 Dan Road, Canton, Massachusetts 02021 (together with its successors and assigns, the ?Company?), and [name of board member] (the ?Director?). WHEREAS
May 11, 2021	EX-10.2	Change in Control Retention Agreement between Organogenesis Holdings Inc. and Gary S. Gillheeney, Sr. effective as of May 10, 2021 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on May 10, 2021) Exhibit 10.2 CHANGE IN CONTROL RETENTION AGREEMENT This Change in Control Retention Agreement (this ?Agreement?) is entered into as of May 10, 2021, by and between Organogenesis Holdings Inc., a Delaware corporation with its principal offices located at 85 Dan Road, Canton, Massachusetts 02021 (together with its successors and assigns, the ?Company?), and Gary S. Gillheeney, Sr. (the ?Executive?).
May 11, 2021	EX-10.3	Form of Change in Control Retention Agreement (Non-CEO Executive Officers) (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on May 10, 2021) Exhibit 10.3 CHANGE IN CONTROL RETENTION AGREEMENT This Change in Control Retention Agreement (this ?Agreement?) is entered into as of [DATE], by and between Organogenesis Holdings Inc., a Delaware corporation with its principal offices located at 85 Dan Road, Canton, Massachusetts 02021 (together with its successors and assigns, the ?Company?), and [name of executive] (the ?Executive?). WHEREAS,
May 11, 2021	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS INC
May 11, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class o SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Vice President and General Counsel Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02
May 11, 2021	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorp
May 11, 2021	EX-99.1	CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE CORRECTING and REPLACING ? Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) ? In a release issued under the same headline earlier today by Organogenesis Holdings Inc. (Nasdaq: ORGO), please note that in the third bullet of the First Quarter 2021 Financial Results Summary, the net revenue from th
May 10, 2021	EX-99.2	Organogenesis Appoints Jon Giacomin to Board of Directors Exhibit 99.2 FOR IMMEDIATE RELEASE Organogenesis Appoints Jon Giacomin to Board of Directors CANTON, Mass., May 10, 2021 ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Jon Gi
May 10, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commission
May 10, 2021	EX-99.1	Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results CANTON, Mass. (May 10, 2021) ? Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial
May 10, 2021	EX-10.1	Fifth Amendment to Credit Agreement dated and effective as of May 5, 2021 among Organogenesis Holdings Inc., Organogenesis Inc. and Prime Merger Sub, LLC, collectively as borrower, and Silicon Valley Bank, in its capacity as the Issuing Lender and Swingline Lender, Silicon Valley Bank, as Administrative Agent, and Silicon Valley Bank and the other lenders listed therein, collectively as Lenders. Exhibit 10.1 FIFTH AMENDMENT TO CREDIT AGREEMENT This Fifth Amendment to Credit Agreement (this ?Amendment?) dated and effective as of May 5, 2021 (the ?Fifth Amendment Effective Date?) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (?Holdings?), ORGANOGENESIS INC., a Delaware corporation (?Organogenesis?) and PRIME MERGER SUB, LLC, a Delaware limited liability company (?Prime?,
April 30, 2021	10-K/A	Annual Report - 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
April 2, 2021	EX-10.1	Fourth Amendment to Credit Agreement dated March 31, 2021 among Organogenesis Holdings Inc., Organogenesis Inc. and Prime Merger Sub, LLC, collectively as borrower, and Silicon Valley Bank, in its capacity as the Issuing Lender and Swingline Lender, Silicon Valley Bank, as Administrative Agent, and Silicon Valley Bank and the other lenders listed therein, collectively as Lenders. Exhibit 10.1 FOURTH AMENDMENT TO CREDIT AGREEMENT This Fourth Amendment to Credit Agreement (this ?Amendment?) is dated and effective as of March 31, 2021 (the ?Fourth Amendment Effective Date?) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (?Holdings?), ORGANOGENESIS INC., a Delaware corporation (?Organogenesis?) and PRIME MERGER SUB, LLC, a Delaware limited liability company (
April 2, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 31, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss
March 16, 2021	EX-99.1	Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year 2021 Guidance EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year 2021 Guidance CANTON, Mass. (March 16, 2021) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care
March 16, 2021	EX-21.1	Subsidiaries of Organogenesis Holdings Inc. Exhibit 21.1 SUBSIDIARIES OF ORGANOGENESIS HOLDINGS INC. NAME OF ORGANIZATION JURISDICTION Organogenesis Inc. Delaware Prime Merger Sub, LLC Delaware Organogenesis Switzerland GmbH Switzerland
March 16, 2021	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
March 16, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 16, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commiss
February 16, 2021	EX-99.1	Organogenesis Appoints David C. Francisco as Chief Financial Officer EX-99.1 FOR IMMEDIATE RELEASE Organogenesis Appoints David C. Francisco as Chief Financial Officer CANTON, Mass., February 16, 2021 — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, announces the appointment of D
February 16, 2021	EX-10.1	Offer Letter dated January 15, 2021 between the Company and David C. Francisco (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on February 16, 2021) Exhibit 10.1 January 13, 2021 David Francisco Dear Dave, This letter is to offer you the position of Chief Financial Officer of Organogenesis Holdings Inc. (the ?Company?), reporting to the Company?s Chief Executive Officer. This offer is contingent on completion of a satisfactory background and reference check. Your first day of employment with the Company (your ?Start Date?) is expected to be Mo
February 16, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 16, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
January 13, 2021	EX-99.1	Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020 EX-99.1 2 d931089dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020 CANTON, Mass. (January 13, 2021) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wou
January 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2021 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (C
December 18, 2020	8-K	Submission of Matters to a Vote of Security Holders - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 18, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (
December 10, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 10, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
December 10, 2020	EX-99.1	Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healt Corporate Presentation December 2020 STRICTLY CONFIDENTIAL Exhibit 99.1 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms ?Organogenesis,? ?Company,? ?we,? ?us? and ?our? refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporation, and its subsidiaries.
November 20, 2020	DEF 14A	- DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 19, 2020	SC 13D/A	ORGO / Organogenesis Holdings Inc. / Ades Alan A. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Organogenesis Holdings Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68621F102 (CUSIP Number) Lori Freedman Vice President and General Counsel Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02
November 19, 2020	SC 13D/A	ORGO / Organogenesis Holdings Inc. / Avista Acquisition Corp. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Amendment No.
November 18, 2020	EX-10.1	Fee Letter Agreement dated November 12, 2020 by and among the Company, the Avista Funds and the Management Company (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on November 18, 2020) EX-10.1 Exhibit 10.1 November 12, 2020 Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 Attn: Gary S. Gillheeney, Sr., President and Chief Executive Officer Re: Fee Letter Agreement Ladies and Gentlemen: This fee letter agreement (the “Agreement”) confirms the agreement by and among Organogenesis Holdings Inc. (the “Company”), Avista Capital Partners IV, L.P. (“Avista IV”), Avis
November 18, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (
November 16, 2020	424B4	17,500,000 Shares Class A Common Stock 424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-249531 PROSPECTUS 17,500,000 Shares Class A Common Stock We are offering 17,500,000 shares of our Class A common stock. Our Class A common stock is listed on the Nasdaq Capital Market under the symbol “ORGO.” On November 12, 2020, the last reported sale price of our Class A common stock was $3.67 per share. Investing in
November 10, 2020	S-1/A	As filed with the Securities and Exchange Commission on November 10, 2020. S-1/A Table of Contents As filed with the Securities and Exchange Commission on November 10, 2020.
November 10, 2020	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 [?] Shares Organogenesis Holdings Inc. Class A Common Stock, $0.0001 par value UNDERWRITING AGREEMENT [?], 2020 MORGAN STANLEY & CO. LLC SVB LEERINK LLC As Representatives (the ?Representatives?) of the Several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway New York, N.Y. 10036 c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, N.Y. 10019 Dear Sirs: 1. Intro
November 10, 2020	CORRESP	- CORRESP Organogenesis Holdings Inc. 85 Dan Road Canton, Massachusetts 02021 November 10, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Organogenesis Holdings Inc. Registration Statement on Form S-1 File No. 333-249531 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933
November 10, 2020	CORRESP	- CORRESP November 10, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Abby Adams Re: Organogenesis Holdings Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-249531 Acceleration Request Requested Date: November 12, 2020 Requested Time: 4:00 p.m. Eastern Daylight Time Ladies and Gentlemen: As representati
November 10, 2020	EX-24.3	Power of Attorney, relating to David Erani Exhibit 24.3 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS that the individual whose signature appears below constitutes and appoints each of Gary S. Gillheeney, Sr. and Henry Hagopian as such person?s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person?s name, place and stead, in any and all capacities, to sign any and all a
November 10, 2020	EX-24.2	Power of Attorney, relating to Robert Ades EX-24.2 Exhibit 24.2 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS that the individual whose signature appears below constitutes and appoints each of Gary S. Gillheeney, Sr. and Henry Hagopian as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any a
November 9, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (C
November 9, 2020	EX-99.1	Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results CANTON, Mass. (November 9, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine market
November 9, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37906 ORGANOGENESIS HOLDINGS
November 3, 2020	8-K	Shareholder Director Nominations - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (C
October 22, 2020	LETTER	LETTER United States securities and exchange commission logo October 22, 2020 Gary S. Gillheeney, Sr. President and Chief Executive Officer Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02021 Re: Organogenesis Holdings Inc. Registration Statement on Form S-1 Filed October 16, 2020 File No. 333-249531 Dear Mr. Gillheeney: This is to advise you that we have not reviewed and will not review your regist
October 22, 2020	TEXT-EXTRACT	- United States securities and exchange commission logo October 22, 2020 Gary S. Gillheeney, Sr. President and Chief Executive Officer Organogenesis Holdings Inc. 85 Dan Road Canton, MA 02021 Re: Organogenesis Holdings Inc. Registration Statement on Form S-1 Filed October 16, 2020 File No. 333-249531 Dear Mr. Gillheeney: This is to advise you that we have not reviewed and will not review your regist
October 16, 2020	S-1	Power of Attorney (previously filed) S-1 Table of Contents As filed with the Securities and Exchange Commission on October 16, 2020.
October 14, 2020	EX-99.1	Organogenesis Holdings Inc. Reports Preliminary Financial Results for Third Quarter 2020 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Preliminary Financial Results for Third Quarter 2020 CANTON, Mass. (October 14, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine market
October 14, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 14, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (C
September 15, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 15, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Com
September 15, 2020	EX-99.1	1 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Hea EX-99.1 0 Exhibit 99.1 Corporate Presentation September 20200 Exhibit 99.1 Corporate Presentation September 2020 1 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a
August 24, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 18, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commis
August 24, 2020	EX-10.1	Separation Letter Agreement, dated August 24, 2020, between Organogenesis Holdings Inc. and Timothy M. Cunningham (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on August 24, 2020) EX-10.1 Exhibit 10.1 August 24, 2020 Timothy M. Cunningham Dear Tim: The purpose of this letter agreement (the “Agreement”) is to confirm the terms regarding your separation of employment with Organogenesis Holdings Inc. (together with its subsidiaries, the “Company”). 1. Separation of Employment. You acknowledge that your employment with the Company terminated without cause effective August 18, 2
August 24, 2020	EX-99.1	Organogenesis Holdings Inc. Announces Management Change EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Announces Management Change CANTON, Mass. (August 24, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the resignati
August 10, 2020	EX-99.2	Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healt EX-99.2 Corporate Presentation August 2020 Exhibit 99.2 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporation, and its subsidiaries. References in t
August 10, 2020	10-Q	Quarterly Report - 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 10, 2020	EX-99.1	Organogenesis Holdings Inc. Reports Second Quarter and First Half 2020 Financial Results EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter and First Half 2020 Financial Results CANTON, Mass. (August 10, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets
August 10, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Co
July 20, 2020	EX-99.1	Organogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Preliminary Revenue Results for Second Quarter 2020 CANTON, Mass. (July 15, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, t
July 20, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 15, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
July 20, 2020	EX-99.2	Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healt EX-99.2 Corporate Presentation July 2020 Exhibit 99.2 Forward-Looking Statements and Other Important Cautions / Industry and Market Data Unless the context indicates otherwise, the terms “Organogenesis,” “Company,” “we,” “us” and “our” refer to Organogenesis Holdings Inc. (formerly known as Avista Healthcare Public Acquisition Corp.), a Delaware corporation, and its subsidiaries. References in thi
May 11, 2020	EX-10.4	Form of Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q (File No. 001-37906) filed with the SEC on May 11, 2020) EX-10.4 Exhibit 10.4 RESTRICTED STOCK UNIT AGREEMENT Granted by Organogenesis Holdings Inc. Under the 2018 Equity Incentive Plan Organogenesis Holdings Inc. (the “Company”) hereby grants to the person named below (the “Recipient”) restricted stock units (“Restricted Stock Units”), with each such unit representing the right to receive one share of Stock, pursuant to the terms set forth below (the “
May 11, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Commi
May 11, 2020	EX-99.1	Organogenesis Holdings Inc. Reports First Quarter 2020 Financial Results EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports First Quarter 2020 Financial Results CANTON, Mass. (May 11, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported fi
May 11, 2020	10-Q	Quarterly Report - 10-Q 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 29, 2020	10-K/A	Annual Report - 10-K/A 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37906 ORGANOGENESIS HOLDINGS INC.
April 29, 2020	EX-10.43	Summary of Amendment to Severance for Gary S. Gillheeney, Sr. (incorporated by reference to Exhibit 10.43 to the Company’s Annual Report on Form 10-K/A (File No. 001-37906) filed with the SEC on April 29, 2020) EX-10.43 Exhibit 10.43 Summary of Amendment to Severance for Gary S. Gillheeney, Sr. Pursuant to the terms of that certain Amended and Restated Key Employee Agreement dated February 1, 2007 by and between Organogenesis Inc. (the “Company”) and Gary S. Gillheeney, Sr., as amended (the “Agreement”), in connection with a termination of Mr. Gillheeney’s employment by the Company other than for Cause (
April 8, 2020	EX-99.1	Organogenesis Holdings Inc. Reports Preliminary Revenue Results for First Quarter 2020 Withdraws Fiscal Year 2020 Revenue Guidance Announces May 11, 2020 Earnings Conference Call EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Preliminary Revenue Results for First Quarter 2020 Withdraws Fiscal Year 2020 Revenue Guidance Announces May 11, 2020 Earnings Conference Call CANTON, Mass. (April 8, 2020) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization
April 8, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 8, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm
March 30, 2020	EX-10.1	Third Amendment to Credit Agreement dated March 26, 2020 among Organogenesis Holdings Inc., Organogenesis Inc. and Prime Merger Sub, LLC, collectively as borrower, and Silicon Valley Bank, in its capacity as the Issuing Lender and Swingline Lender, Silicon Valley Bank, as Administrative Agent, and Silicon Valley Bank and the other lenders listed therein, collectively as Lenders (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on March 30, 2020) EX-10.1 Exhibit 10.1 THIRD AMENDMENT TO CREDIT AGREEMENT This Third Amendment to Credit Agreement (this “Amendment”) dated and effective as of March 26, 2020 (the “Third Amendment Effective Date”) by and among ORGANOGENESIS HOLDINGS INC., a Delaware corporation (“Holdings”), ORGANOGENESIS INC., a Delaware corporation (“Organogenesis”) and PRIME MERGER SUB, LLC, a Delaware limited liability company
March 30, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 26, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Com
March 16, 2020	EX-10.1	Separation Letter Agreement, dated March 13, 2020, between Organogenesis Holdings Inc. and Howard P. Walthall, Jr. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37906) filed with the SEC on March 16, 2020) EX-10.1 Exhibit 10.1 March 13, 2020 Howard P. Walthall, Jr. Dear Howard: The purpose of this letter agreement (the “Agreement”) is to confirm the terms regarding your separation of employment with Organogenesis Holdings Inc. (together with its subsidiaries, the “Company”). 1. Separation of Employment. You acknowledge that your employment with the Company terminated without Cause effective March 10
March 16, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 10, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Com
March 9, 2020	EX-10.41	Fourth Amendment to Lease dated February 14, 2020 by and between Liberty Industrial Park and Organogenesis Inc. (incorporated by reference to Exhibit 10.41 to the Company’s Annual Report on Form 10-K (File No. 001-37906) filed with the SEC on March 9, 2020) EX-10.41 Exhibit 10.41 FOURTH AMENDMENT TO LEASE (Liberty Industrial Park, LLC) THIS FOURTH AMENDMENT TO LEASE (“Fourth Amendment”) is made and entered into as of the 14th day of February, 2020, by and between LIBERTY INDUSTRIAL PARK, a California limited liability company (“Lessor”) and ORGANOGENESIS INC., a Delaware corporation (“Lessee”). R E C I T A L S: A. Lessor and ADVANCED BIOHEALING, Inc.
March 9, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 9, 2020 ORGANOGENESIS HOLDINGS INC. (Exact Name of Registrant as specified in its charter) Delaware 001-37906 98-1329150 (State or Other Jurisdiction of Incorporation) (Comm

AHPAW / OmniAb Inc - Warrants (01/11/2027) - Depositi SEC, Relazione annuale, dichiarazione di delega

Statistiche di base

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?